Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.
PRNewswire - October 18, 1999
Trimeris also has recently entered into a collaboration with F. Hoffmann-La Roche Ltd. for the development and commercialization of T-20, currently in Phase II clinical trials. Trimeris's lead product candidate, T-20, inhibits fusion of HIV with host cells. Unlike traditional AIDS drugs that work in the cell after the virus has taken over its machinery, T-20 attacks HIV outside the cell, before it begins replicating and infecting other cells.
For the past two years, Mallinckrodt scientists have worked closely with scientists from Trimeris to improve and scale up the novel and unique synthetic manufacturing process for T-20 developed by Trimeris. "The requirement for T-20 peptide when it is commercialized will most likely represent the largest volume ever produced for a synthetic peptide of its size and structure," according to Michael J. Collins, president of Mallinckrodt's Pharmaceuticals Group. "We're extremely pleased to be working with Trimeris and Roche and are especially pleased to be able to contribute Mallinckrodt's unique skills in the scale up of complex peptide chemistry to the development of this important and potentially lifesaving new drug," Collins added.
Peptides are chains of amino acids. Mallinckrodt has been involved in small-scale peptides development for about seven years, primarily for use in clinical trials or New Drug Application (NDA) submissions to the U.S. Food and Drug Administration (FDA).
"This scale-up process performed by Mallinckrodt represents an important milestone in the manufacture of T-20," stated Dr. Dani Bolognesi, chief executive officer of Trimeris. "The quality of T-20 produced by Mallinckrodt's manufacturing team is excellent," Bolognesi added.
Mallinckrodt Inc. is a global manufacturer and marketer of specialty medical products in three essential areas of healthcare -- analgesic pharmaceuticals, diagnostic imaging and respiratory care. Based in St. Louis, Mo., the company operates in more than 100 countries and had fiscal 1999 net sales of $2.6 billion. The Mallinckrodt website address is http://www.mallinckrodt.com .
CONTACT: Media, Barbara Abbett, 314-654-5230, barbara.abbett@mkg.com, or Investors, Barbara Gould, 314-654-3190, Invest@mkg.com, both of Mallinckrodt.
SOURCE Mallinckrodt, Inc.
991018
PR991035
Copyright © 1999 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .